Diagnostic Microbiology and Infectious Disease

(The H4-Index of Diagnostic Microbiology and Infectious Disease is 24. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 500 papers]. The publications cover those that have been published in the past four years, i.e., from 2019-11-01 to 2023-11-01.)
Clinical, molecular, and epidemiological characterization of the SARS-CoV-2 virus and the Coronavirus Disease 2019 (COVID-19), a comprehensive literature review246
Evaluation of a commercially-available surrogate virus neutralization test for severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2)72
The use of copper to help prevent transmission of SARS-coronavirus and influenza viruses. A general review65
Monitoring antibody response following SARS-CoV-2 infection: diagnostic efficiency of 4 automated immunoassays51
Seroprevalence of SARS-CoV-2 (COVID-19) among healthcare workers in Saudi Arabia: comparing case and control hospitals47
Evaluation of the Cue Health point-of-care COVID-19 (SARS-CoV-2 nucleic acid amplification) test at a community drive through collection center40
COVID-19 in Brazil: 150,000 deaths and the Brazilian underreporting37
The risk factors associated with MERS-CoV patient fatality: A global survey36
In Vitro Activity of Cefiderocol, a Novel Siderophore Cephalosporin, against Gram-Negative Bacilli Isolated from Patients in Canadian Intensive Care Units35
Comparative study of four SARS-CoV-2 Nucleic Acid Amplification Test (NAAT) platforms demonstrates that ID NOW performance is impaired substantially by patient and specimen type35
Evaluation of the BioFire® COVID-19 test and Respiratory Panel 2.1 for rapid identification of SARS-CoV-2 in nasopharyngeal swab samples35
Determinants of prolonged viral RNA shedding in hospitalized patients with SARS-CoV-2 infection32
How many are we missing with ID NOW COVID-19 assay using direct nasopharyngeal swabs? Findings from a mid-sized academic hospital clinical microbiology laboratory32
In vitro time-kill kinetics of dalbavancin against Staphylococcus spp. biofilms over prolonged exposure times29
Lower persistence of anti-nucleocapsid compared to anti-spike antibodies up to one year after SARS-CoV-2 infection29
The potential of volatile organic compounds-based breath analysis for COVID-19 screening: a systematic review & meta-analysis.28
Comparison of SARS-CoV-2 IgM and IgG seroconversion profiles among hospitalized patients in two US cities28
Evaluation of the performance of SARS-CoV-2 serological tools and their positioning in COVID-19 diagnostic strategies28
COVID-19 – 6 million cases worldwide and an overview of the diagnosis in Brazil: a tragedy to be announced28
Duration of SARS-CoV-2 viremia and its correlation to mortality and inflammatory parameters in patients hospitalized for COVID-19: a cohort study27
Comparison of ceftazidime-avibactam and ceftolozane-tazobactam in vitro activities when tested against gram-negative bacteria isolated from patients hospitalized with pneumonia in United States medica26
Bacterial and fungal pathogens isolated from patients with bloodstream infection: frequency of occurrence and antimicrobial susceptibility patterns from the SENTRY Antimicrobial Surveillance Program (25
Performance of a multiplex polymerase chain reaction panel for identifying bacterial pathogens causing pneumonia in critically ill patients with COVID-1925
Changes in healthcare managing COVID and non–COVID-19 patients during the pandemic: striking the balance24